Market Cap 1.53B
Revenue (ttm) 109.79M
Net Income (ttm) -153.49M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -139.80%
Debt to Equity Ratio -1.53
Volume 927,500
Avg Vol 873,066
Day's Range N/A - N/A
Shares Out 48.72M
Stochastic %K 73%
Beta 1.58
Analysts Strong Sell
Price Target $35.78

Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology; Mitomycin a generic drug used off-label as an adjuvant chemotherapy for the treatment of low-grade NMIBC after trans-urethral resection of bladder tumor; Zusduri, a sustained-release formulation of mitomycin for the treatment of non-muscle invasiv...

Industry: Biotechnology
Sector: Healthcare
Phone: 646 768 9780
Address:
400 Alexander Park Drive, 4th Floor, Princeton, United States
ivocsev
ivocsev May. 12 at 1:42 AM
$URGN what’s next?
3 · Reply
chickenboy
chickenboy May. 12 at 1:05 AM
$URGN Short interest continues to drop from 7.8M to 7.2M.
0 · Reply
cloudhedge
cloudhedge May. 11 at 4:41 PM
$URGN Q1 numbers are absolute fire. Zusduri sales hit $29.2MM, up 109% Q/Q and smashing consensus by 33%. The prescriber data is the real story: unique prescribers grew 151% while repeaters surged 222%, now making up 40% of the base. Growth remained consistent heading into Q2. This isn’t just a beat; it’s a massive commercial inflection point for the bulls. Follow me 👉 @cloudhedge for real-time updates and everything. Let’s make moves!
1 · Reply
Rockemsock
Rockemsock May. 11 at 2:50 PM
0 · Reply
Quantumup
Quantumup May. 11 at 2:41 PM
Truist⬆️the PT on $CGON to $77, reiterated at Buy, and said: BLA Submission Completion in 4Q26. $URGN $TYRA TARA JNJ MRK IBRX Truist added—The 1Q26 update includes a narrowed timeline for BLA submission completion to 4Q26 (from 2026), which we view as a largely benign clearing event that provides a cleaner setup into PIVOT-006 readout. We continue to see the 1H26 PIVOT-006 topline as a high-impact catalyst, given the breadth of the IR NMIBC opportunity and CGON's potential ~18+ month lead versus competitors. We also look to the upcoming CORE-008 Cohort CX update as directional — early, but potentially informative on Creto's combination strategies. We update our model for the quarter, reiterating our Buy rating and raising our PT to $77 (from $75).
0 · Reply
notreload_ai
notreload_ai May. 11 at 2:40 PM
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 10 at 9:16 PM
$URGN hey look it finally hit... that was like 1487 strategies ago. careful now
0 · Reply
GeniusLoci
GeniusLoci May. 9 at 8:38 PM
$URGN New 52 Week High + Pocket Pivot
0 · Reply
ybk1234
ybk1234 May. 8 at 6:04 PM
$URGN bo. It's soon
1 · Reply
deweyeggbert
deweyeggbert May. 8 at 2:29 PM
$URGN out for now.
2 · Reply
Latest News on URGN
UroGen Pharma assumed with a Buy at Ladenburg

2026-05-11T15:30:55.000Z - 1 day ago

UroGen Pharma assumed with a Buy at Ladenburg


UroGen Pharma to Present at Upcoming Investor Conferences

May 7, 2026, 8:00 AM EDT - 6 days ago

UroGen Pharma to Present at Upcoming Investor Conferences


UroGen Pharma reports Q1 EPS (47c), consensus (36c)

2026-05-07T03:46:46.000Z - 6 days ago

UroGen Pharma reports Q1 EPS (47c), consensus (36c)


UroGen Pharma Earnings Call Transcript: Q1 2026

May 6, 2026, 10:00 AM EDT - 6 days ago

UroGen Pharma Earnings Call Transcript: Q1 2026


UroGen Pharma initiated with a Buy at Jefferies

2026-04-09T20:26:32.000Z - 4 weeks ago

UroGen Pharma initiated with a Buy at Jefferies


UroGen Pharma Earnings Call Transcript: Q4 2025

Mar 2, 2026, 10:00 AM EST - 2 months ago

UroGen Pharma Earnings Call Transcript: Q4 2025


UroGen Pharma reports Q4 EPS (54c), consensus (51c)

2026-03-02T13:06:31.000Z - 2 months ago

UroGen Pharma reports Q4 EPS (54c), consensus (51c)


UroGen Pharma sees FY26 net sales for Jelmyto $97M-$101M

2026-03-02T13:05:45.000Z - 2 months ago

UroGen Pharma sees FY26 net sales for Jelmyto $97M-$101M


UroGen Pharma says permanent J Code for ZUSDURI now in effect

2026-01-05T13:37:35.000Z - 4 months ago

UroGen Pharma says permanent J Code for ZUSDURI now in effect


UroGen Pharma files automatic mixed securities shelf

2025-11-06T21:32:03.000Z - 6 months ago

UroGen Pharma files automatic mixed securities shelf


UroGen Pharma Earnings Call Transcript: Q3 2025

Nov 6, 2025, 10:00 AM EST - 6 months ago

UroGen Pharma Earnings Call Transcript: Q3 2025


UroGen Pharma reports Q3 EPS (69c), consensus (68c)

2025-11-06T13:06:45.000Z - 6 months ago

UroGen Pharma reports Q3 EPS (69c), consensus (68c)


UroGen Pharma Transcript: AGM 2025

Aug 26, 2025, 10:00 AM EDT - 9 months ago

UroGen Pharma Transcript: AGM 2025


UroGen Pharma Earnings Call Transcript: Q2 2025

Aug 7, 2025, 10:00 AM EDT - 9 months ago

UroGen Pharma Earnings Call Transcript: Q2 2025


UroGen Pharma Transcript: Study Update

Jun 13, 2025, 8:30 AM EDT - 11 months ago

UroGen Pharma Transcript: Study Update


US FDA approves Urogen's bladder cancer drug

Jun 12, 2025, 12:48 PM EDT - 11 months ago

US FDA approves Urogen's bladder cancer drug


ivocsev
ivocsev May. 12 at 1:42 AM
$URGN what’s next?
3 · Reply
chickenboy
chickenboy May. 12 at 1:05 AM
$URGN Short interest continues to drop from 7.8M to 7.2M.
0 · Reply
cloudhedge
cloudhedge May. 11 at 4:41 PM
$URGN Q1 numbers are absolute fire. Zusduri sales hit $29.2MM, up 109% Q/Q and smashing consensus by 33%. The prescriber data is the real story: unique prescribers grew 151% while repeaters surged 222%, now making up 40% of the base. Growth remained consistent heading into Q2. This isn’t just a beat; it’s a massive commercial inflection point for the bulls. Follow me 👉 @cloudhedge for real-time updates and everything. Let’s make moves!
1 · Reply
Rockemsock
Rockemsock May. 11 at 2:50 PM
0 · Reply
Quantumup
Quantumup May. 11 at 2:41 PM
Truist⬆️the PT on $CGON to $77, reiterated at Buy, and said: BLA Submission Completion in 4Q26. $URGN $TYRA TARA JNJ MRK IBRX Truist added—The 1Q26 update includes a narrowed timeline for BLA submission completion to 4Q26 (from 2026), which we view as a largely benign clearing event that provides a cleaner setup into PIVOT-006 readout. We continue to see the 1H26 PIVOT-006 topline as a high-impact catalyst, given the breadth of the IR NMIBC opportunity and CGON's potential ~18+ month lead versus competitors. We also look to the upcoming CORE-008 Cohort CX update as directional — early, but potentially informative on Creto's combination strategies. We update our model for the quarter, reiterating our Buy rating and raising our PT to $77 (from $75).
0 · Reply
notreload_ai
notreload_ai May. 11 at 2:40 PM
0 · Reply
Sw1ngb0t
Sw1ngb0t May. 10 at 9:16 PM
$URGN hey look it finally hit... that was like 1487 strategies ago. careful now
0 · Reply
GeniusLoci
GeniusLoci May. 9 at 8:38 PM
$URGN New 52 Week High + Pocket Pivot
0 · Reply
ybk1234
ybk1234 May. 8 at 6:04 PM
$URGN bo. It's soon
1 · Reply
deweyeggbert
deweyeggbert May. 8 at 2:29 PM
$URGN out for now.
2 · Reply
JuggernautRaider
JuggernautRaider May. 8 at 2:07 PM
$URGN Urogen has been crushing it on behalf of bladder cancer patients 🚀 great company
0 · Reply
Golanh
Golanh May. 8 at 2:07 PM
$URGN 🔥
0 · Reply
BioStick123
BioStick123 May. 7 at 7:25 PM
Biotech Buy of the Year - A year later today, the new buy of the year is $IVVD - we have a potential Phase 3 runup coming shortly and Phase 3 should be de-risked by its already-commercial COVID antibody infusion asset. IVVD has 200 million in cash with last round priced at $2.50 - now trading at $1.40 approaching the end of a catalyst-desert. Phase 3 readout for a <500M peak rev drug (COVID antibody for immunocomprised and elderly who do not respond well to vaccines), potentially much higher if efficacy for overall population is better than vaccines or if FDA makes a move against the vaccines. Readout in Q3'25. Long Covid Phase 2, vaccine comparitor trial and pipeline provide upside. $URGN $XBI
1 · Reply
BioStick123
BioStick123 May. 7 at 7:20 PM
0 · Reply
BrunoGOudega
BrunoGOudega May. 7 at 6:44 PM
$URGN If you ask ChatGPT what price the stock will be at a revenue of $1B, well, $26 is not even close.
0 · Reply
GeniusLoci
GeniusLoci May. 7 at 6:26 PM
0 · Reply
deweyeggbert
deweyeggbert May. 7 at 4:43 PM
$URGN Oppenheimer raised target from $31 to $40 today.
0 · Reply
TPapreee
TPapreee May. 6 at 6:22 PM
$URGN great progress love to see it
0 · Reply
deweyeggbert
deweyeggbert May. 6 at 5:52 PM
$URGN now let's see some analysts upgrades and get this up over $30 again.
1 · Reply
ivocsev
ivocsev May. 6 at 5:41 PM
0 · Reply
Night_Owl_Biotech
Night_Owl_Biotech May. 6 at 3:21 PM
The graph compres $URGN Year 1 - 7 (FY26 - 32) analyst consensus to the Year 1 - 7 (FY24 - 30) revenue forecast prepared by $DCPH management/BOD presented Ono when Ono opted to acquire DCPH for an enterprise value of ~$2.1B. URGN analyst consensus is provided as well as the lowest URGN analyst estimate. URGN consensus is as of the morning of 5/6/26, before URGN announced Q126 sales exceeded analyst estimates by over 10%. Hence it is likely URGN estimates will be revised higher than what is reflected on the attachment. Per Seeking Alpha, there are 8 analysts who cover URGN. Five analysts provide FY26 - 30 estimates. All 5 analysts project URGN to generate more revenues over the next 5 years than DCPH. If analysts believe URGN will generate 15-20% more revenues, does that mean, in theory, URGN is worth 15-20% more in a hypothetical M&A exit? This is not investment advice but if URGN was ever considering a M&A exit, there does not appear to be a better time, but WTF do we know $XBI $IBB
0 · Reply
Klipse05
Klipse05 May. 6 at 3:17 PM
$URGN better earnings...still lost roughly 22 million and still 200 plus million in debt...
1 · Reply